Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Insider Sale: Director at $ROIV Sells 150,000 Shares

Automated

KEITH S MANCHESTER, a director at $ROIV, sold 150,000 shares of the company on 11-19-2025 for an estimated $3,030,000. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.8% of their shares of this class of stock. Following this trade, they now own 18,347,727 shares of this class of $ROIV stock.

$ROIV Insider Trading Activity

ROIV Insider Trades

$ROIV insiders have traded $ROIV stock on the open market 41 times in the past 6 months. Of those trades, 1 have been purchases and 40 have been sales.

Here’s a breakdown of recent trading of $ROIV stock by insiders over the last 6 months:

  • VIVEK RAMASWAMY has made 0 purchases and 10 sales selling 5,520,855 shares for an estimated $81,934,925.
  • ERIC VENKER (President & Immunovant CEO) has made 0 purchases and 18 sales selling 4,853,209 shares for an estimated $71,489,370.
  • KEITH S MANCHESTER has made 0 purchases and 4 sales selling 1,300,000 shares for an estimated $26,304,500.
  • FINANCIAL LP QVT has made 0 purchases and 4 sales selling 1,300,000 shares for an estimated $26,304,500.
  • DANIEL ALLEN GOLD has made 0 purchases and 4 sales selling 1,300,000 shares for an estimated $26,304,500.
  • MATTHEW GLINE (CEO) purchased 3,315 shares for an estimated $49,957

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ROIV Hedge Fund Activity

We have seen 187 institutional investors add shares of $ROIV stock to their portfolio, and 184 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ROIV Congressional Stock Trading

Members of Congress have traded $ROIV stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $ROIV stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$ROIV Analyst Ratings

Wall Street analysts have issued reports on $ROIV in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Citigroup issued a "Buy" rating on 11/11/2025
  • HC Wainwright & Co. issued a "Buy" rating on 09/18/2025
  • JP Morgan issued a "Overweight" rating on 09/18/2025
  • Guggenheim issued a "Buy" rating on 09/18/2025
  • Leerink Partners issued a "Outperform" rating on 09/18/2025
  • Jefferies issued a "Buy" rating on 09/18/2025
  • Goldman Sachs issued a "Buy" rating on 09/18/2025

To track analyst ratings and price targets for $ROIV, check out Quiver Quantitative's $ROIV forecast page.

$ROIV Price Targets

Multiple analysts have issued price targets for $ROIV recently. We have seen 8 analysts offer price targets for $ROIV in the last 6 months, with a median target of $20.5.

Here are some recent targets:

  • Samantha Semenkow from Citigroup set a target price of $26.0 on 11/11/2025
  • Brian Cheng from JP Morgan set a target price of $20.0 on 09/18/2025
  • Yatin Suneja from Guggenheim set a target price of $21.0 on 09/18/2025
  • David Risinger from Leerink Partners set a target price of $22.0 on 09/18/2025
  • Chi Fong from B of A Securities set a target price of $16.5 on 09/18/2025
  • Dennis Ding from Jefferies set a target price of $20.0 on 09/18/2025
  • Corinne Jenkins from Goldman Sachs set a target price of $24.0 on 09/18/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles